The Limited Times

Now you can see non-English news...

Covid-19: unresolved questions about the effectiveness of AstraZeneca's vaccine formula


To date, uncertainty remains about the vaccine's ability to protect people over 65, who are poorly represented in the Lancet trial.

Since Tuesday, the European Medicines Agency (EMA) examines the application for marketing authorization for the vaccine developed by the University of Oxford and the AstraZeneca laboratory.

This British product is cheaper than its RNA competitors from Pfizer / BioNTech and Moderna because its technology is less complex.

It uses a chimpanzee adenovirus rendered harmless and used as a vector for the gene inducing the production of the spike protein, typical of Sars-CoV-2.

As for the two anti-Covid vaccines already endorsed by the agency, AstraZeneca began in October to communicate to the agency the first results.

Enough to allow the EMA to deliver its verdict in an accelerated manner on January 29, and the High Authority for Health (HAS) to position it in the French vaccine strategy in the wake.

Although a green light is expected for this third vaccine candidate, already authorized in the UK and India, questions about its effectiveness still arise.

Read also:

Covid-19: why vaccines definitely limit contagiousness

Out of the four clinical tests

This article is for subscribers only.

You have 75% left to discover.

Subscribe: 1 € the first month

Can be canceled at any time


Already subscribed?

Log in

Source: lefigaro

All tech articles on 2021-01-13

You may like

News/Politics 2020-10-01T02:56:40.619Z

Trends 24h

Tech/Game 2021-01-23T09:25:28.822Z


© Communities 2019 - Privacy